@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev
@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2
@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce
> San Francisco-based Sympara Medical raised $5.5 million in funding to use towards the development of a device to treat hypertension. More
> EndoStim, a company selling neurostimulation devices used to treat gastroesophageal reflux disease, postponed its IPO on Thursday citing poor market conditions. More
> Zyno Medical received 510(k) clearance for its Nimbus Ambulatory Infusion Pump designed to deliver medications and fluids to a patient needing subcutaneous, epidural, perineural or intravenous infusions. Release
> Cardiovascular medical device company Sorin Group expanded its Munich, Germany manufacturing facility to develop more cardiopulmonary technology. Release
Biotech News
@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech
@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce
@DamianFierce: $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce
@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce
> AstraZeneca gets some EU encouragement for its $2B cancer hopeful. More
> Shire CFO to exit in wake of failed AbbVie deal. Chutes & Ladders
> NPS Pharma will have to wait another three months for an FDA OK. News
Pharma News
@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma
@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce
> Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings. Story
> What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid? More
> Actavis primed for another deal, or two, or maybe three. Article